Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells

Cytokine

Volumn 63, Issue 2, 2013, Pages 187-193

  Zgheib, Alain ^a   Pelletier Bonnier, Émilie ^a   Levros, Louis Charles ^a   Annabi, Borhane ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

G CSF; GM CSF; Mesenchymal stromal cells; MT1 MMP; STAT3

Indexed keywords

COLONY STIMULATING FACTOR 1; CONCANAVALIN A; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JANUS KINASE; JANUS KINASE 2; MATRIX METALLOPROTEINASE 14; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN; TOFACITINIB;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CSF 2 GENE; CSF 3 GENE; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; JAK1 GENE; JAK2 GENE; JAK3 GENE; MESENCHYMAL STROMA CELL; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TYK2 GENE;

CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CONCANAVALIN A; ENZYME INHIBITORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; JANUS KINASES; MACROPHAGE COLONY-STIMULATING FACTOR; MATRIX METALLOPROTEINASE 1; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; TRANSCRIPTION, GENETIC; TYK2 KINASE; TYRPHOSTINS;

EID: 84878982477     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.04.027     Document Type: Article

References (58)

1. Auletta J.J., Deans R.J., Bartholomew A.M. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012, 119:1801-1809.
2. Bunnell B.A., Betancourt A.M., Sullivan D.E. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther 2010, 1:34.
3. DelaRosa O., Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediator Inflamm 2010, 865601.
4. Kanellopoulos J.M., De Petris S., Leca G., Crumpton M.J. The mitogenic lectin from Phaseolus vulgaris does not recognize the T3 antigen of human T lymphocytes. Eur J Immunol 1985, 15:479-486.
5. Ferriz-Martinez RA, Torres-Artega IC, Blanco-Labra A, Garcia-Gasca T. The role of plant lectins in cancer treatment. New approaches in the treatment of cancer: Nova Science; 2010. p. 71-89.
6. Unitt J., Hornigold D. Plant lectins are novel Toll-like receptor agonists. Biochem Pharmacol 2011, 81:1324-1328.
7. Annabi B., Thibeault S., Lee Y.T., Bousquet-Gagnon N., Eliopoulos N., Barrette S., et al. Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Exp Hematol 2003, 31:640-649.
8. Fortier S., Touaibia M., Lord-Dufour S., Galipeau J., Roy R., Annabi B. Tetra- and hexavalent mannosides inhibit the pro-apoptotic, antiproliferative and cell surface clustering effects of concanavalin-A: impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells. Glycobiology 2008, 18:195-204.
9. Scheibe F., Ladhoff J., Huck J., Grohmann M., Blazej K., Oersal A., et al. Immune effects of mesenchymal stromal cells in experimental stroke. J Cereb Blood Flow Metab 2012, 32:1578-1588.
10. Nishimura H., Nishimura M., Oda R., Yamanaka K., Matsubara T., Ozaki Y., et al. Lectins induce resistance to proteases and/or mechanical stimulus in all examined cells-including bone marrow mesenchymal stem cells-on various scaffolds. Exp Cell Res 2004, 295:119-127.
11. Akla N., Pratt J., Annabi B. Concanavalin-A triggers inflammatory response through JAK/STAT3 signalling and modulates MT1-MMP regulation of COX-2 in mesenchymal stromal cells. Exp Cell Res 2012, 318:2498-2506.
12. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62:3603-3608.
13. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
14. Annabi B., Naud E., Lee Y.T., Eliopoulos N., Galipeau J. Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. J Cell Biochem 2004, 91:1146-1158.
15. Birnbaum T., Roider J., Schankin C.J., Padovan C.S., Schichor C., Goldbrunner R., et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neuro-Oncol 2007, 83:241-247.
16. Le Blanc K., Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:321-334.
17. Dazzi F., Lopes L., Weng L. Mesenchymal stromal cells: a key player in 'innate tolerance'?. Immunology 2012, 137:206-213.
18. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene; in press.
19. Bexell D., Gunnarsson S., Tormin A., Darabi A., Gisselsson D., Roybon L., et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 2009, 17:183-190.
20. Al-Khaldi A., Al-Sabti H., Galipeau J., Lachapelle K. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg 2003, 75:204-209.
21. Chen S., Liu Z., Tian N., Zhang J., Yei F., Duan B., et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006, 18:552-556.
22. Wong R.S. Mesenchymal stem cells: angels or demons?. J Biomed Biotechnol 2011, 2011:459510.
23. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98:1076-1084.
24. Majumdar M.K., Thiede M.A., Haynesworth S.E., Bruder S.P., Gerson S.L. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000, 9:841-848.
25. Bussolino F., Ziche M., Wang J.M., Alessi D., Morbidelli L., Cremona O., et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991, 87:986-995.
26. Karow M., Popp T., Egea V., Ries C., Jochum M., Neth P. Wnt signalling in mouse mesenchymal stem cells: impact on proliferation, invasion and MMP expression. J Cell Mol Med 2009, 13:2506-2520.
27. Gingras D., Michaud M., Di Tomasso G., Béliveau E., Nyalendo C., Béliveau R. Sphingosine-1-phosphate induces the association of membrane-type 1 matrix metalloproteinase with p130Cas in endothelial cells. FEBS Lett 2008, 582:399-404.
28. Uekita T., Gotoh I., Kinoshita T., Itoh Y., Sato H., Shiomi T., et al. Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the Cupin superfamily. A possible multifunctional protein acting as an invasion suppressor down-regulated in tumors. J Biol Chem 2004, 279:12734-12743.
29. Proulx-Bonneau S., Guezguez A., Annabi B. A concerted HIF-1α/MT1-MMP signalling axis regulates the expression of the 3BP2 adaptor protein in hypoxic mesenchymal stromal cells. PLoS One 2011, 6:e21511.
30. Nyalendo C., Michaud M., Beaulieu E., Roghi C., Murphy G., Gingras D., et al. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J Biol Chem 2007, 282:15690-15699.
31. Lord-Dufour S., Copland I.B., Levros L.C., Post M., Das A., Khosla C., et al. Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells. Stem Cells 2009, 27:489-497.
32. Nyalendo C., Beaulieu E., Sartelet H., Michaud M., Fontaine N., Gingras D., et al. Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis 2008, 29:1655-1664.
33. Sina A., Proulx-Bonneau S., Roy A., Poliquin L., Cao J., Annabi B. The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway. J Cell Commun Signal 2010, 4:31-38.
34. Pratt J., Roy R., Annabi B. Concanavalin-A-induced autophagy biomarkers requires membrane type-1 matrix metalloproteinase intracellular signalling in glioblastoma cells. Glycobiology 2012, 22:1245-1255.
35. Cuiffo B.G., Karnoub A.E. Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh Mig. 2012, 6:220-230.
36. Ribatti D. Angiogenic activity of classical hematopoietic cytokines. Leuk Res 2012, 36:537-543.
37. Zeng J., Xie K., Wu H., Zhang B., Huang C. Identification and functional study of cytokines and chemokines involved in tumorigenesis. Comb Chem High Throughput Screen 2012, 15:276-285.
38. Torsvik A., Bjerkvig R. Mesenchymal stem cell signalling in cancer progression. Cancer Treat Rev 2012, 39:180-188.
39. Klopp A.H., Gupta A., Spaeth E., Andreeff M., Marini F. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem cells 2011, 29:11-19.
40. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
41. Copland I., Sharma K., Lejeune L., Eliopoulos N., Stewart D., Liu P., et al. CD34 expression on murine marrow-derived mesenchymal stromal cells: impact on neovascularization. Exp Hematol 2008, 36:93-103.
42. Rubbia-Brandt L., Sappino A.P., Gabbiani G. Locally applied GM-CSF induces the accumulation of alfa-smooth actin containing myofibroblasts. Virchows Arch B 1991, 60:73-82.
43. Bussolino F., Ziche M., Wang J.M., Alessi D., Morbidelli L., Cremona O., et al. In vitro and in vivo activation of endothelial cells by colony stimulating factors. J Clin Invest 1991, 87:986-991.
44. Bocchietto E., Guglielmetti A., Silvagno F., Taraboletti G., Pescarmona G., Mantovani A., et al. Proliferation and migratory responses of murine microvascular endothelial cells to granulocyte-colony stimulating factor. J Cell Physiol 1993, 155:89-95.
45. Mueller M.M., Herold-Mende C.C., Riede D., Lange M., Steiner H.H., Fusenig N.E. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 1999, 155:1557-1567.
46. Revoltella R.P., Menicagli M., Campani D. Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas. Cytokine 2012, 57:347-359.
47. Wang J., Yao L., Zhao S., Zhang X., Yin J., Zhang Y., et al. Granulocyte-colony stimulating factor promotes proliferation, migration and invasion in glioma cells. Cancer Biol Ther 2012, 13:389-400.
48. Hu X., Chen J., Wang L., Ivashkiv L.B. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 2007, 82:237-243.
49. Arroyo A.G., Genís L., Gonzalo P., Matías-Román S., Pollán A., Gálvez B.G. Matrix metalloproteinases: new routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease. Curr Pharm Des 2007, 13:1787-1802.
50. Remacle A.G., Golubkov V.S., Shiryaev S.A., Dahl R., Stebbins J.L. Chernov, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res 2012, 72:2339-2349.
51. Sina A., Lord-Dufour S., Annabi B. Cell-based evidence for aminopeptidase N/CD13 inhibitor actinonin targeting of MT1-MMP-mediated proMMP-2 activation. Cancer Lett 2009, 279:171-176.
52. Ingvarsen S., Porse A., Erpicum C., Maertens L., Jürgensen H.J., Madsen D.H., et al. Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP. Impact on lymphangiogenesis. J Biol Chem 2013, 288:10195-10204.
53. Zinöcker S., Vaage J.T. Rat mesenchymal stromal cells inhibit T cell proliferation but not cytokine production through inducible nitric oxide synthase. Front Immunol. 2012, 3:62.
54. Duffy M.M., Pindjakova J., Hanley S.A., McCarthy C., Weidhofer G.A., Sweeney E.M., et al. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 2011, 41:2840-2851.
55. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005, 12:47-57.
56. Liu G., Atteridge C.L., Wang X., Lundgren A.D., Wu J.D. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 2010, 184:3346-3350.
57. Kajita M., Itoh Y., Chiba T., Mori H., Okada A., Kinoh H., et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001, 153:893-904.
58. Annabi B., Thibeault S., Moumdjian R., Béliveau R. Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells. J Biol Chem 2004, 279:21888-21896.